LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Home・Akciju saraksts・OraSure Technologies Inc

OraSure Technologies Inc

Slēgts

SektorsVeselības aprūpe

2.85 3.64

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.71

Max

2.9

Galvenie mērījumi
By Trading Economics
Ienākumi	-30M -14M
Pārdošana	27M 27M
Peļņas marža	-50.626
Darbinieki	501
EBITDA	3.2M -11M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 25. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	5.9M 201M
Iepriekšējā atvēršanas cena	-0.79
Iepriekšējā slēgšanas cena	2.85

Ziņu noskaņojums

By Acuity

34%

66%

103 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

N/A / 2.975 Atbalsts un pretestība

OraSure Technologies Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. febr. 22:31 UTC

Peļņas

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

2026. g. 18. febr. 22:18 UTC

Peļņas

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

2026. g. 18. febr. 22:11 UTC

Peļņas

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

2026. g. 18. febr. 21:52 UTC

Peļņas

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

2026. g. 18. febr. 23:56 UTC

Tirgus saruna

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

2026. g. 18. febr. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 18. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

2026. g. 18. febr. 23:34 UTC

Tirgus saruna

Peļņas

Brambles' Cost Control Stands Out to Bull -- Market Talk

2026. g. 18. febr. 23:33 UTC

Tirgus saruna

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

2026. g. 18. febr. 23:32 UTC

Tirgus saruna

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

2026. g. 18. febr. 22:45 UTC

Peļņas

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

2026. g. 18. febr. 22:44 UTC

Tirgus saruna

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

2026. g. 18. febr. 22:37 UTC

Peļņas

Nutrien 4Q EPS $1.18 >NTR.T

2026. g. 18. febr. 22:37 UTC

Peļņas

Nutrien 4Q Sales $5.34B >NTR.T

2026. g. 18. febr. 22:35 UTC

Peļņas

Pan American Silver 4Q EPS $1.07 >PAAS

2026. g. 18. febr. 22:35 UTC

Peļņas

Pan American Silver 4Q Rev $1.18B >PAAS

2026. g. 18. febr. 22:30 UTC

Peļņas

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

2026. g. 18. febr. 22:29 UTC

Peļņas

Kinross Gold 4Q EPS 75c >K.T

2026. g. 18. febr. 22:22 UTC

Peļņas

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

2026. g. 18. febr. 22:22 UTC

Tirgus saruna

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

2026. g. 18. febr. 22:16 UTC

Peļņas

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

2026. g. 18. febr. 22:05 UTC

Peļņas

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

2026. g. 18. febr. 22:03 UTC

Peļņas

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q Sales $929M >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q EPS $1.68 >KALU

2026. g. 18. febr. 22:00 UTC

Peļņas

Kinross Gold 4Q Adj EPS 67c >KGC

2026. g. 18. febr. 22:00 UTC

Peļņas

Kinross Gold 4Q Sales $2.02B >KGC

2026. g. 18. febr. 21:56 UTC

Peļņas

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

2026. g. 18. febr. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

OraSure Technologies Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam OraSure Technologies Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

N/A / 2.975Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There are no events.

Noskaņojums

By Acuity

103 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par OraSure Technologies Inc

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.